A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).

• Phase: Phase 3

Details

• Lead Sponsor: Kissei Pharmaceutical Co., Ltd.
• Collaborators: JCR Pharmaceutical Co., Ltd.; JCR Pharmaceuticals Co., Ltd.
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• Patients being treated with Darbepoetin alfa.

Exclusion Criteria:

• Patients having complication or history of a cardiovascular / lung / brain infarction.

• Patients having a pronounced hemorrhagic lesion.